State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, PR China; Co-Innovation Center for Sustainable Forestry in Southern China, Nanjing Forestry University, Nanjing, 210037, PR China.
State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, PR China; Co-Innovation Center for Sustainable Forestry in Southern China, Nanjing Forestry University, Nanjing, 210037, PR China.
Biomed Pharmacother. 2018 Jan;97:656-666. doi: 10.1016/j.biopha.2017.10.159. Epub 2017 Nov 6.
In current study, a series of shikonin derivatives were synthesized and its anticancer activity was evaluated. As a result, PMMB232 showed the best antiproliferation activity with an IC value of 3.25±0.35μM. Further, treatment of HeLa cells with a variety of concentrations of target drug resulted in dose-dependent event marked by apoptosis. What's more, the mitochondrial potential (Δym) analysis was consistent with the apoptosis result. In addition, PARP was involved in the progress of apoptosis revealed by western blotting. To identify the detailed role and mechanism of PMMB232 in the progression of human cervical cancer, we detected the expression of HIF-1α and E-cadherin in HeLa cells. Results showed that expression of HIF-1α was downregulated, while E-cadherin protein was upregulated. Meanwhile, glycolysis related protein PDK1 was decreased in HeLa cells. Conversely, the expression of PDH-E1α was upregulated. Docking simulation results further indicate that PMMB232 could be well bound to HIF-1α. Taken together, our data indicate that compound PMMB232 could be developed as a potential anticancer agent.
在本研究中,我们合成了一系列紫草素衍生物,并评估了它们的抗癌活性。结果表明,化合物 PMMB232 表现出最好的增殖抑制活性,IC 值为 3.25±0.35μM。进一步的研究表明,用不同浓度的目标药物处理 HeLa 细胞会导致凋亡的剂量依赖性事件。此外,线粒体膜电位(Δym)分析与凋亡结果一致。此外,Western blot 结果显示 PARP 参与了凋亡的进程。为了确定 PMMB232 在人宫颈癌进展中的详细作用和机制,我们检测了 HeLa 细胞中 HIF-1α 和 E-cadherin 的表达。结果表明,HIF-1α 的表达下调,而 E-cadherin 蛋白表达上调。同时,HeLa 细胞中糖酵解相关蛋白 PDK1 减少,而 PDH-E1α 的表达上调。对接模拟结果进一步表明,PMMB232 可以很好地与 HIF-1α 结合。综上所述,我们的数据表明,化合物 PMMB232 可以作为一种有潜力的抗癌药物进行开发。